Current Edition

AbbVie

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are …

Continue Reading →
AbbVie

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and …

Continue Reading →
AbbVie

As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case

On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to …

Continue Reading →
AbbVie

AbbVie’s Rinvoq, Pfizer’s Xeljanz and Lilly’s Olumiant slapped with new FDA warnings amid JAK safety crackdown

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed …

Continue Reading →
AbbVie

AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns

AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients, potentially adding another arrow to the company’s post-Humira quiver. The …

Continue Reading →
AbbVie

Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut

Alvotech, the biosim specialist locked in a legal battle over AbbVie’s sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic …

Continue Reading →
AbbVie

AbbVie’s ‘unsupported’ price hikes on Humira drove $1.4B in extra U.S. drug spending, ICER says

Over the years, the Institute for Clinical and Economic Review (ICER) has emerged as a champion in the fight against high U.S. drug costs. In …

Continue Reading →
AbbVie

Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival …

Continue Reading →
AbbVie

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, …

Continue Reading →
AbbVie

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Continue Reading →